1. Home
  2. NKSH vs BNR Comparison

NKSH vs BNR Comparison

Compare NKSH & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NKSH

National Bankshares Inc.

HOLD

Current Price

$37.10

Market Cap

237.1M

Sector

Finance

ML Signal

HOLD

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

HOLD

Current Price

$20.85

Market Cap

252.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NKSH
BNR
Founded
1891
2014
Country
United States
China
Employees
N/A
N/A
Industry
Major Banks
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
237.1M
252.7M
IPO Year
1995
2019

Fundamental Metrics

Financial Performance
Metric
NKSH
BNR
Price
$37.10
$20.85
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
65.9K
33.1K
Earning Date
04-23-2026
06-05-2026
Dividend Yield
4.04%
N/A
EPS Growth
100.81
N/A
EPS
2.49
N/A
Revenue
$8,176,000.00
N/A
Revenue This Year
N/A
$111.65
Revenue Next Year
N/A
N/A
P/E Ratio
$14.95
N/A
Revenue Growth
9.39
N/A
52 Week Low
$24.74
$2.18
52 Week High
$40.00
$41.72

Technical Indicators

Market Signals
Indicator
NKSH
BNR
Relative Strength Index (RSI) 50.54 54.25
Support Level $35.41 $19.72
Resistance Level $38.07 $23.80
Average True Range (ATR) 0.82 1.45
MACD 0.07 0.76
Stochastic Oscillator 49.81 76.52

Price Performance

Historical Comparison
NKSH
BNR

About NKSH National Bankshares Inc.

National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural loans, commercial real estate, construction loans for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary. The company earns its revenue from interest and fees on loans, non-interest income, and investments.

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.

Share on Social Networks: